New NNRTI doravirine shows good efficacy in phase 3 study
Dual antiretroviral regimen maintains durable HIV suppression after switch
Integrase inhibitor bictegravir matches dolutegravir for first-line HIV treatment
The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study
Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV
Four days on, three days off HIV treatment controls viral load in French pilot study
Darunavir/ritonavir & lamivudine matches triple-drug therapy
New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy
